Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Mar 1;22(5):1031-3.
doi: 10.1158/1078-0432.CCR-15-2494. Epub 2015 Dec 4.

Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?

Yu-Xiao Yang  1 , Anil K Rustgi  2
Affiliations
Comment

Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?

Yu-Xiao Yang et al. Clin Cancer Res. .

Abstract

Metformin offers no survival advantage in patients with metastatic pancreatic cancer. Despite promising experimental evidence suggesting an antitumor effect of metformin, its impact on the survival of advanced pancreatic cancer is likely very limited. Future studies may need to consider its role in early-stage pancreatic cancer. See related article by Reni et al., p. 1076.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1
Proposed Mechanisms Linking Diabetes, Metformin and Pancreatic Cancer
See this image and copyright information in PMC

Comment on

References

    1. Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase 2 trial. Clin Cancer Res. 2015 Oct 12; Epub ahead of print. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. - PMC - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. - PubMed
    1. Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World J Gastroenterol. 2015;21(20):6127–45. - PMC - PubMed

Publication types